Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports. They currently have a $155.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 5.37% from the company’s current price.
A number of other equities analysts have also recently weighed in on GILD. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday. Truist Financial boosted their price objective on Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank Of Canada upped their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $159.26.
View Our Latest Stock Report on Gilead Sciences
Gilead Sciences Stock Performance
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the prior year, the firm posted $2.01 earnings per share. The company’s revenue was up 10.6% compared to the same quarter last year. On average, analysts expect that Gilead Sciences will post -0.48 earnings per share for the current year.
Insiders Place Their Bets
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the transaction, the chief financial officer owned 164,096 shares in the company, valued at approximately $23,841,507.84. This trade represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the sale, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 105,000 shares of company stock valued at $14,940,540. 0.30% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Gilead Sciences
A number of hedge funds have recently modified their holdings of GILD. Apella Capital LLC lifted its stake in shares of Gilead Sciences by 19.9% in the third quarter. Apella Capital LLC now owns 2,889 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 480 shares in the last quarter. Everhart Financial Group Inc. grew its stake in Gilead Sciences by 8.0% during the 3rd quarter. Everhart Financial Group Inc. now owns 10,418 shares of the biopharmaceutical company’s stock valued at $1,553,000 after acquiring an additional 772 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in Gilead Sciences by 17.4% during the 3rd quarter. Valeo Financial Advisors LLC now owns 9,819 shares of the biopharmaceutical company’s stock valued at $1,464,000 after acquiring an additional 1,452 shares in the last quarter. New Covenant Trust Company N.A. acquired a new stake in Gilead Sciences in the 3rd quarter valued at about $253,000. Finally, Toth Financial Advisory Corp lifted its stake in Gilead Sciences by 85.5% in the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 100 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: JPMorgan raised its price target to $170 from $160 and reaffirmed an “overweight” rating, implying substantial upside and reflecting increased confidence in Gilead’s earnings and pipeline prospects. JPMorgan analyst action
- Positive Sentiment: Truist lifted its target to $158 from $150 and retained a “buy” rating, citing a more constructive view of Gilead’s valuation and growth outlook. Truist analyst action
- Positive Sentiment: Cantor Fitzgerald reaffirmed its “overweight” rating with a $155 target, indicating further potential appreciation from recent trading levels. Cantor Fitzgerald analyst action
- Positive Sentiment: Gilead extended its oncology research collaboration with Nurix Therapeutics (NASDAQ: NRIX) by two years. The partnership could provide Gilead with additional protein-degradation drug candidates, while Nurix remains eligible for up to approximately $1.30 billion in potential payments plus royalties. Nurix collaboration extension
- Neutral Sentiment: Gilead signed a five-year DevOps agreement with Cognizant to combine life-sciences expertise with technical services. The deal should support operational efficiency but is unlikely to materially change near-term financial results. Cognizant DevOps agreement
- Negative Sentiment: RBC raised its target to $126 from $123 but maintained a “sector perform” rating. The new target remains below Gilead’s recent share price, signaling that RBC considers the stock fully valued or overvalued despite the modest increase. RBC analyst action
Gilead Sciences Company Profile
Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.
Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.
Read More
- Five stocks we like better than Gilead Sciences
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
